Protalix director gets 17K options, 8.5K RSUs

PLX director Christian Elze received new stock options and RSUs vesting quarterly from a September 3, 2026 grant.

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. (PLX) reported that director Christian Elze received equity-based awards on September 3, 2026. He was granted 17,000 stock options to buy common stock at an exercise price of $2.59 per share and 8,500 restricted stock units, all held directly. The options and RSUs each vest in 12 equal quarterly installments commencing on the grant date. A separate footnote states he also holds options to purchase 15,000 shares at $1.64 per share expiring September 3, 2035. No Rule 10b5‑1 trading plan is reported for these awards.

Insider Trade Summary

Grant/Award: 25,500 shares

Grant/Award 2 txns

Insider Elze Christian

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy) F1, F2	17,000	$0.00	$0.00
Grant/Award	Restricted Stock Units F3, F4	8,500	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 17,000 contracts (Direct); Restricted Stock Units — 8,500 contracts (Direct)

Footnotes (4)

1. F1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
2. F2. Does not include options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
3. F3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
4. F4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

Key Figures

Stock options granted: 17,000 options Option exercise price: $2.59 per share Options expiration date: September 3, 2036 +3 more

6 metrics

Stock options granted 17,000 options Grant to director Christian Elze on September 3, 2026

Option exercise price $2.59 per share Exercise price for 17,000 options granted September 3, 2026

Options expiration date September 3, 2036 Expiration for 17,000 options granted to Christian Elze

Restricted stock units granted 8,500 RSUs Grant to director Christian Elze on September 3, 2026

Vesting schedule 12 equal quarterly installments Applies separately to both the 17,000 options and 8,500 RSUs

Existing options referenced 15,000 options at $1.64 per share Separate options expiring on September 3, 2035, not part of new grant

Key Terms

Stock Options (Right to Buy), Restricted Stock Units, exercise price, vesting

4 terms

Stock Options (Right to Buy) financial

"security title is listed as Stock Options (Right to Buy)"

Restricted Stock Units financial

"security title is listed as Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"options to purchase 15,000 shares of common stock at an exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares of common stock underlying the RSUs vest in 12 equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What equity awards did PLX director Christian Elze receive on September 3, 2026?

He received 17,000 stock options with an exercise price of $2.59 per share and 8,500 restricted stock units, each RSU representing one share of common stock upon vesting.

How do the new PLX stock options for Christian Elze vest?

The 17,000 stock options vest in 12 equal quarterly installments commencing on the grant date of September 3, 2026, and are exercisable at $2.59 per share until their expiration on September 3, 2036.

How do the new PLX restricted stock units for Christian Elze vest?

The 8,500 restricted stock units vest in 12 equal quarterly installments commencing on the grant date. Each RSU represents the right to receive, following vesting, one share of Protalix BioTherapeutics common stock.

Did Christian Elze report any sales of PLX shares in this Form 4?

No. The Form 4 reports only acquisitions of stock options and restricted stock units as compensation; there are no reported sales or dispositions of Protalix BioTherapeutics common stock in this filing.

What existing PLX options holdings for Christian Elze are referenced in the filing?

A footnote states that he also holds options to purchase 15,000 shares of common stock at an exercise price of $1.64 per share, which expire on September 3, 2035 and are not included in the newly reported 17,000 options.

Was a Rule 10b5-1 trading plan involved in these PLX transactions?

No. The filing’s Rule 10b5‑1 checkbox is not marked, and there is no footnote indicating these awards were made under a Rule 10b5‑1 trading plan or other pre-arranged trading arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 06:04 AM Accepted by SEC EDGAR 09/04/2026 - 06:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elze Christian

(Last) (First) (Middle)

2 SNUNIT STREET

SCIENCE PARK

(Street)

CARMIEL 2161401

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$2.59	09/03/2026		A		17,000		(1)	09/03/2036	Common Stock	17,000	$0	17,000(2)	D
Restricted Stock Units	(3)	09/03/2026		A		8,500		(4)	(4)	Common Stock	8,500	$0	8,500	D

Explanation of Responses:

1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

2. Does not include options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

	/s/ Joseph R. Magnas, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)